FiercePharma

As Vertex works through CF combos, it's looking to Gilead's example: executive

Vertex is working to snag reimbursement for its cystic fibrosis combo Orkambi in France, where uptake has been strong. () Which biotech company does Vertex admire? Hint: It’s one some analysts think ...
Business Wire

Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes

-Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex ...
The Motley Fool

3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow

Vertex Pharmaceuticals has built a billion-dollar cystic fibrosis business over time. But the company today may be preparing for a new era of growth, thanks to the strength of its pipeline. This ...
Business Wire

Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a ...
Nasdaq

Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear?

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined around 1.2% in the past three months, losing almost $3 billion of its market value. A key reason for the stock price dip was the loss ...
The Motley Fool

3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow

As mentioned, the import tariff situation looks less daunting now than it did several weeks ago. Still, uncertainty remains, as the U.S. still must reach agreements with many countries worldwide -- ...